Prostate Cancer Risk: MRI Surveillance
- For men undergoing active surveillance for prostate cancer, MRI-led monitoring can effectively determine risk, according to a new study.
- The study, spearheaded by Cameron Englman at University College London, followed 1,150 patients starting active surveillance between February 2000 and July 2023.
- researchers divided patients into four groups based on Gleason score (3+3 vs.
MRI-led monitoring significantly impacts prostate cancer risk assessment, offering crucial insights for those in active surveillance.A recent study reveals that the visibility of tumors on MRI scans, combined with the presence of a Gleason pattern 4, accelerates disease progression, underscoring the importance of vigilant monitoring. Researchers tracked over a thousand patients, revealing how adhering to MRI and biopsy schedules directly influences outcomes. The five-year event-free survival rates highlighted the distinct risk profiles associated with different Gleason scores and MRI findings. For many, choosing the right proactive approach will be critical. The ten-year rates for treatments underscored the necessity of regular check-ups. News Directory 3’s coverage emphasizes the need for advanced, risk-adapted active surveillance. Discover what’s next for prostate cancer management.
MRI Monitoring Effective for Prostate Cancer Active Surveillance
For men undergoing active surveillance for prostate cancer, MRI-led monitoring can effectively determine risk, according to a new study. The research, focusing on risk-adapted active surveillance, found that the visibility of tumors on MRI scans and the presence of a Gleason pattern 4 were associated with quicker disease progression and the need for treatment.
The study, spearheaded by Cameron Englman at University College London, followed 1,150 patients starting active surveillance between February 2000 and July 2023. All participants had a Gleason score of 3+4 or lower, a prostate-specific antigen (PSA) level below 20 ng/mL, and at least two MRI scans. During the first year, PSA levels were checked three to four times, then twice annually. MRIs were conducted at the start and after 12 months; those with visible lesions on the initial MRI had another scan at 24 months.
researchers divided patients into four groups based on Gleason score (3+3 vs. 3+4) and MRI visibility (visible vs. non-visible disease). The main goal was to measure event-free survival, where an event meant a Gleason score of 4+3 or higher, or the start of any prostate cancer treatment.The median follow-up was 64 months and 72 months for 732 patients without an event.
the study revealed that 64% of patients initially had a Gleason score of 3+3, while 36% had 3+4. Among those with a Gleason score of 3+4, 49% had tumors visible on MRI.
Event-free survival rates varied significantly among the risk groups. The five-year rates were 91% for non-visible Gleason 3+3, 71% for MRI-visible Gleason 3+3, 71% for non-visible Gleason 3+4, and 44% for MRI-visible Gleason 3+4.
Of the 487 patients who had follow-up biopsies, 67 saw their cancer progress to a Gleason score of 4+3 or higher. For non-visible Gleason 3+3 cases, the rates of progression to a Gleason score of 4+3 or higher were 1.2% at five years and 6.1% at 10 years. in contrast, those with MRI-visible Gleason 3+4 disease at the start had rates of 17% and 43%, respectively.
Metastasis to the lymph nodes or bones occurred in 10 patients, but only in those who skipped recommended follow-up MRIs or biopsies. The 10-year rate of starting treatment ranged from 28% for those with non-visible Gleason 3+3 disease to 85% for those with MRI-visible Gleason 3+4 disease. For non-visible Gleason 3+4, the rate was 46%, while it was 54% for MRI-visible Gleason 3+3.
“Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes,” the authors wrote.
What’s next
Englman and colleagues suggest that active surveillance patients can be safely monitored using MRI, with biopsy decisions guided by MRI results and PSA level changes. They emphasize the need for prospective, multi-center clinical trials to further assess this approach.